EbrahimSDelpassandMD

Nuclear Medicine • Houston, TX

Physician

Join to view full profile

Dr. Delpassand is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Delpassand's full profile

Already have an account?

Office
9701 Richmond Ave
Ste 122
Houston, TX 77042
Phone+1 713-781-6200

Fax+1 713-781-6206

Education & Training

Baylor College of MedicineResidency, Pathology-Anatomic and Clinical, 1990 - 1991
Baylor College of MedicineResidency, Nuclear Medicine, 1988 - 1990
Tehran University of Medical Sciences School of MedicineClass of 1982

Certifications & Licensure

TX State Medical License 1990 - 2025
OK State Medical License 1988 - 1992
American Board of Nuclear Medicine Nuclear Medicine

Clinical Trials

Injection Methods in Finding the Sentinel Lymph Node During Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Invasive Breast Cancer Start of enrollment: 2005 Jun 01
Completed
Not Applicable
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors Start of enrollment: 2005 Aug 01
Completed
Phase 2, Phase 3
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms Start of enrollment: 2010 Oct 27
Completed
Phase 2
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours Start of enrollment: 2012 Sep 06
Completed
Phase 3
68-Ga-DOTATATE PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs) Start of enrollment: 2013 Mar 01
Completed
Not Applicable
Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy Start of enrollment: 2017 Jul 12
Terminated
Phase 2
Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET Start of enrollment: 2018 Feb 05
Recruiting
Phase 1
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE Start of enrollment: 2018 Aug 23
Completed
Phase 3
Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). Start of enrollment: 2021 Dec 16
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1785 citations
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan R. Strosberg, Ghassan El-Haddad, Edward M. Wolin, Andrew Eugene Hendifar, James C. Yao
The New England Journal of Medicine. 2017-01-11
114 citations
The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature.
Alireza Mojtahedi, Sanjay Thamake, Izabela Tworowska, David Ranganathan, Ebrahim S. Delpassand
American Journal of Nuclear Medicine and Molecular Imaging. 2014-08-15
87 citations
The safety of lymphatic mapping in pregnant breast cancer patients using Tc-99m sulfur colloid.
Angela J. Keleher, Richard Wendt, Ebrahim S. Delpassand, Anne Stachowiak, Henry Mark Kuerer
The Breast Journal. 2004-11-01

Press Mentions

Right to Try Is Unleashing the Future of MedicineSeptember 13th, 2022
Vect-Horus and RadioMedix Announce FDA Approval of Exploratory IND of Diagnostic 68 Ga-RMX-VH in Glioblastoma MultiformeJuly 8th, 2021
RadioMedix & Curium Announce Detectnetᵀᴹ (Copper Cu 64 Dotatate Injection) Inclusion on NCCN Guidelines®May 5th, 2021
Join now to see all

EbrahimSDelpassandMD

Dr. Delpassand is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.